<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8081">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01713504</url>
  </required_header>
  <id_info>
    <org_study_id>CHRU of Lille</org_study_id>
    <nct_id>NCT01713504</nct_id>
  </id_info>
  <brief_title>Identification of New Markers in the Hypereosinophilic Syndrome</brief_title>
  <acronym>SHE</acronym>
  <official_title>Identification of New Markers in the Hypereosinophilic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <authority>France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to characterize new hypereosinophilic syndrome biomarkers more informative
      and more accessible compared to those that we have already thanks to a proteomic approach.
      This will help the investigators to diagnose the this disease.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2010</start_date>
  <completion_date type="Anticipated">June 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>The aim is to characterize, through an approach immunoprotéomique, new HES biomarkers more informative and easier access than those currently available to us. These biomarkers will help to the diagnosis of HES, compared with other causes of eosinophilia.</measure>
    <time_frame>one month after patient inclusion</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Hypereosinophilic Syndrome</condition>
  <arm_group>
    <arm_group_label>Hypereosinophilic syndrome unexplained</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Hypereosinophilic syndrome explained</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Normal rate of eosinophilic</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>biologie sample</intervention_name>
    <description>comparison of biomarkers between HES, HE biomarkers data and control arms</description>
    <arm_group_label>Hypereosinophilic syndrome unexplained</arm_group_label>
    <arm_group_label>Hypereosinophilic syndrome explained</arm_group_label>
    <arm_group_label>Normal rate of eosinophilic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  dated and signed informed consent

          -  virale serology negative or negative result less than 6 months

          -  virale serology negative for HBV or vaccinated patient

          -  insured

          -  virale serology negative or negative result less than 6 months

          -  negative pregnancy test or female menopause for at least 1 year

        Exclusion Criteria:

          -  subject enable adult, under guardianship or under protective measures of justice

          -  Refusal or inability to give informed consent

          -  The hypereosinophilic syndrome explained origin other than  than atopy, bullous
             pemphigoid, the Churg-Strauss syndrome and DRESS
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lionel Prin, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Lille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lionel Prin, MD PhD</last_name>
    <phone>(33)320 445 574</phone>
    <email>l-prin@chru-lille.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>University hospital</name>
      <address>
        <city>Lille</city>
        <state>Nord</state>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lionel Prin, MD PhD</last_name>
      <phone>(33)320 445 574</phone>
      <email>l-prin@hru-lille.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Hatron, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <lastchanged_date>October 23, 2012</lastchanged_date>
  <firstreceived_date>October 22, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hypereosinophilic Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
